Search clinical trials for: BI 1701963

Total 1211 results

Boehringer Ingelheim

Completed

Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male Subjects

Healthy
University of Arizona

Completed

Unilateral Massage as a Potential Treatment for Depression

Depression

United States
Logan College of Chiropractic

Completed

A Pilot Investigational Study: Treatment of Anxiety With Non-Needle Electro-Acupuncture

Anxiety, Mild to Moderate

United States
Boehringer Ingelheim

Withdrawn

Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

Hepatitis C, Chronic

Australia, Spain, Sweden
Boehringer Ingelheim

Completed

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

Schizophrenia

United States, United Kingdom, Australia, Canada, France, New Zealand
Boehringer Ingelheim

Completed

Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)

Healthy

Germany
Japan Clinical Oncology Group
Ministry of Health, Labour and Welfare, Japan

Terminated

Study of Standard CHOP Versus Biweekly CHOP in Aggressive Non-Hodgkin's Lymphoma (JCOG9809)

Non-Hodgkin's Lymphoma

Japan
Abcentra

Completed

A Proof-of-Activity Study With Orticumab in Subjects With Psoriasis and Cardiometabolic Risk Factors

Coronary Artery Disease | Inflammation | Psoriasis | Cardiometabolic Syndrome

United States
Boehringer Ingelheim

Completed

BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell

Germany, Belgium, France
First Affiliated Hospital of Wenzhou Medical University
Shanghai Zhongshan Hospital; Sir Run Run Shaw Hospital; Wuhan Asia Heart Hospital and other collaborators

Unknown

Comparison of His Bundle Pacing and Bi-Ventricular Pacing in Heart Failure With Atrial Fibrillation

Heart Failure | Atrial Fibrillation

China
Boehringer Ingelheim

Completed

Safety and Tolerability of BI 638683 After Single Rising Oral Doses in Healthy Male Subjects

Healthy

Germany
Boehringer Ingelheim

Terminated

A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19

COVID-19

United States, Spain
Boehringer Ingelheim

Completed

Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male Subjects

Healthy
Boehringer Ingelheim

Completed

Bioavailability of BI 1356 After Single Oral Administration Given as Different Tablet Formulation in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Not yet recruiting

Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma

Advanced Soft Tissue Sarcoma | Undifferentiated Pleomorphic Sarcoma (UPS) | Myxofibrosarcoma (MFS)
Boehringer Ingelheim

Completed

Study to Investigate the Relative Bioavailability, Influence of Pantoprazole Coadministration and Food Effect of Different Oral Formulation of BI 113608

Healthy

Germany
Boehringer Ingelheim

Completed

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

Pulmonary Disease, Chronic Obstructive

Australia, Austria, Canada, France, Germany
Boehringer Ingelheim

Completed

Relative Bioavailability of Empagliflozin (BI 10773) (Final Formulation) Compared to Empagliflozin (BI 10773 XX) (Trial Formulation 2) in Healthy Male and Female Volunteers

Healthy

Germany
University of Michigan
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Completed

SafERteens M-Coach

Alcohol Drinking | Violence

United States
Shanghai Chest Hospital

Completed

Adjunctive Right Atrial Ablation for Persistent Atrial Fibrillation With Right Atrial Enlargement

Persistent Atrial Fibrillation | Right Atrial Enlargement

China
Boehringer Ingelheim

Completed

A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.

Asthma

Austria, Germany, Poland, Romania, Slovakia, Slovenia
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease

Crohn Disease

United States, Belgium, Germany, Hungary, Spain, United Kingdom, Denmark, Czechia, Poland, Italy, Netherlands
Boehringer Ingelheim

Completed

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

Kidney Disease, Chronic

United States, Spain, Korea, Republic of, Belgium, Australia, Hong Kong, India, Canada, China, Germany, Italy, Japan, Malaysia, Finland, Switzerland, Turkey, Hungary, Poland, Portugal, Philippines, Czechia, Greece, Bulgaria, Brazil, Arg... and more
Boehringer Ingelheim

Completed

Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design

Diabetes Mellitus, Type 2

Canada, Croatia, Estonia, France, Germany, India, Lithuania, Mexico, Netherlands, Romania, Russian Federation, Sweden, Tunisia, Ukraine
AbbVie

Completed

A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

United States
University of Turin, Italy
Butterfly Network

Completed

POCUS for Difficult Peripheral Access in the Emergency Department - a RCT

Emergencies | Vascular Access

Italy
Boehringer Ingelheim

Completed

BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)

Lymphoma, Non-Hodgkin

Korea, Republic of, Germany, France
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1356 BS as Tablet in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
University of Alabama at Birmingham
United States Department of Defense

Not yet recruiting

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

Sarcoma | NF1 | MPNST

United States
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, Germany, Greece, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico and more
Chang Gung Memorial Hospital

Completed

Effects of Intensive Robot-assisted Therapy in Patients With Subacute Stroke (RT)

Stroke

Taiwan
Amal Therapeutics
Boehringer Ingelheim

Active, not recruiting

Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer (KISIMA-01)

Metastatic Colorectal Cancer | Colorectal Cancer | Liver Metastasis Colon Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | MSS

United States, Belgium, Switzerland, Germany
Boehringer Ingelheim

Completed

BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and Immunogenicity

Crohn Disease

Serbia, United Kingdom, United States, Czechia, Germany, Greece, Poland, Russian Federation, Turkey, Israel, Belarus, Ukraine, Croatia, Bosnia and Herzegovina
Boehringer Ingelheim

Completed

BI 443651 Methacholine Challenge

Asthma

United Kingdom
Boehringer Ingelheim

Completed

Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis

Psoriasis

United States, Germany, Russian Federation, Czechia, Poland, Ukraine, Estonia, Slovakia
Boehringer Ingelheim

Completed

A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected Patients

Hepatitis C

United States, Austria, Belgium, Canada, France, Germany, Japan, Korea, Republic of, Portugal, Romania, Russian Federation, Spain, Switzerland, Taiwan, United Kingdom
Boehringer Ingelheim

Terminated

Single Rising Dose Study of BI 201335 ZW in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Withdrawn

A Phase III Study of BI201335 in Treatment-naive and Prior Relapser Patients With Chronic Hepatitis C Infection

Hepatitis C, Chronic
Boehringer Ingelheim

Completed

Efficacy and Safety of 3 Doses of BI1356 (Linagliptin) in Type 2 Diabetes Patients

Diabetes Mellitus, Type 2

United States, Australia, Canada, Czech Republic, Russian Federation, Ukraine
Boehringer Ingelheim

Not yet recruiting

A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy

Diabetic Retinopathy
Boehringer Ingelheim

Completed

BI 1356 BS in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Completed

Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

BI 44370 TA in Acute Migraine Attack

Migraine Disorders

Belgium, El Salvador, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom
Boehringer Ingelheim

Completed

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II

Pulmonary Disease, Chronic Obstructive

Austria, Belgium, Canada, Germany, Russian Federation
BioInvent International AB

Active, not recruiting

BI-1607 in Combination With Trastuzumab in Subjects With HER2-positive Advanced Solid Tumors (CONTRAST)

HER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | HER2-positive Metastatic Breast Cancer

Spain, United Kingdom, Germany
Lawson Health Research Institute

Not yet recruiting

Bi-level vs. Single Level ESB in VATS

Acute Pain

Canada
Boehringer Ingelheim

Completed

A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic Pulmonary Fibrosis

Spain, United States, Canada, Korea, Republic of, Australia, Italy, United Kingdom, Germany, China, Finland, Denmark, Netherlands, Greece, Argentina, Austria, Chile, Czechia, Hungary, Japan, Poland, Russian Federation, Ukraine
Boehringer Ingelheim

Completed

Relative Bioavailability of Multiple Oral Doses of BI 187004 and Metformin After Co-administration Compared to Multiple Oral Doses of BI 187004 Alone and Metformin Alone in Healthy Male Subjects

Healthy

Germany
Boehringer Ingelheim

Completed

Effectiveness and Safety of Different Doses of BI 1026706 in Patients With Postoperative Dental Pain

Pain, Postoperative

Italy
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 1)

Hepatitis C

Austria, Belgium, France, Germany, Japan, Portugal, Romania, Russian Federation, Spain, Switzerland, United Kingdom

Search clinical trials for: BI 1701963

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Taiwan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations